anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To control neurogenic pains caused by various mechanisms.  &lt;P&gt;SOLUTION: This neurogenic pain-eliminating, mitigating or reducing composition comprises one or more substances selected from the group consisting of D-allose, D-allose derivatives, D-psicose and D-psicose derivatives preferably in an amount of 0.01 to 90 wt.% as an effective component. The composition comprises a mixture of D-allose and/or D-allose derivatives, and D-psicose and/or D-psicose derivatives in a ratio of 1:1 to 10:1. The neurogenic pain is caused by a disease selected from the group consisting of trigeminal neuralgia, postoperative pain, periodontitis, gingivitis, stomatitis, oral ulcer, herpes zoster, postherpetic neuralgia, diabetic neuritis, causalgia, phantom limb pain and malignant tumors. A method for using the neurogenic pain-eliminating, mitigating or reducing composition is characterized by giving one or more of the substances to a patient suffered from a neurogenic pain at a dose of 0.01 to 100 g a day.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
The invention relates to a radioimmuno-pharmacon for treating the HIV-1 infection. The disadvantages of standard HIV therapies are that the medicaments currently used must be taken daily in large quantities (approx. 30 tablets per day), in accordance with a strict timetable and for the rest of the patient&#39;s life, and that they cause numerous side effects. In addition, conventional medicaments only reduce the replication of the virus. They do not eliminate the host cells infected with HIV and therefore do not cure the HIV infection. The inventive radioimmuno-pharmacon consists of a monoclonal antibody and a radionuclide for eliminating HIV-replicating cells in patients infected with HIV-1 in vivo after the virus burden has been reduced with an antiretroviral therapy and optionally, with the added protection of a host cell transplantation and with medicamentous protection of thyroid activity. According to the invention, this radioimmuno-pharmacon is administered to the HIV-1-infected patient intravenously, once or in several cycles. It targets and inflicts lasting damage on the host cells in order to eliminate as near to all of them as possible. The aim is to heal the HIV infection or at least slow down the progression of the disease.
The invention relates to a method and system of physician economic performance evaluation in which the relative medical difficulty associated with patients admitted by a particular physician is determined and, given that measurement, judgments made concerning the relative amount of inpatient resources that the physician required. Also, one application of the present invention relates to a method for gainsharing of physician services using a surplus allocation methodology for rewarding physicians in relation to their performance. An incentive pool is determined from previous patient claims and payments made to physicians in advance, such as in a base year. Best practice norms are established for a plurality of classified diagnosis groups. In one embodiment of the present invention, the classified diagnosis related groups are adjusted for severity of illness to compensate for actual clinical challenges faced by individual physicians. The best practice norms can be used in the surplus allocation method for determining physician performance. The incentive is established proportional to the relationship between a physician&#39;s individual performance and the best practice norm.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain functional olive oil containing polyphenol in ≥60% residual ratio based on raw material oil and to provide a use thereof.  &lt;P&gt;SOLUTION: The functional olive oil is obtained by a production method with which only physical operations are performed and no chemical treatment is carried out from oil collection from olive fruits to deodorization treatment, is of a type much containing active ingredients in spite of having no flavor characteristic of olive and contains polyphenol preferably in ≥60% residual ratio based on raw material oil. The method for producing functional olive oil comprises (a) a process for collecting oil from olive fruits and (b) a process for removing a smell component from the obtained oil by a distillation means and carrying out only physical treatments without chemical treatment at all from the process (a) to the process (b). The in vivo antioxidant composition comprises the functional olive oil as an active ingredient. The in vivo antioxidant composition is selected from the group consisting preferably of seasoning, food additive, food material, food and beverage, health food and beverage, external preparation for skin, medicine and feed.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
FIELD: medicine. SUBSTANCE: proposed method of determination of degree of risk of lead intoxication provides for investigation of content of lead in day&#39;s portion of urine and for additional homeocentric biological action on examined person with subsequent determination of content of lead in day&#39;s portion of urine. If increase of content of lead exceeds 10% relative to initial content low degree of risk of lead intoxication is determined. If given factor increases or decreases by not more than 10% or if there is no changes of it moderate degree of risk of lead intoxication is defined. Decrease of this factor by more than 10% defines high degree of risk of lead intoxication. EFFECT: improved authenticity of method. 8 tbl
PURPOSE: To provide a process for producing the attenuated vaccine for varicella zoster viruses(VZV) accompanied by an increase in the yield of the VZV. CONSTITUTION: The VZV infected sensitive cells selected from the human diploid cells are cultured under a sufficiently high nutrition condition until confluent monolayer cultured matter is obtd. These VZV infected cells are infected at the multiplicity of infection as high as possible for practicability and the VZV infected and cultured matter is maintained at the high nutrition state for about 22 to 96 hours. The cultured matter in which the infectious VZV products are maximized is collected. According to this method, the cell density of about 500,000 cells/cm&lt;2&gt; is stationarily obtd. by using a customarily used culture vessel.
In Western medicine, special drugs for treating scrofula haven&#39;t been developed at present, and therapeutic scheme of treating phthisis is commonly adopted in treatment. Those antituberculosis drugs cannot realize the effect of effectively restraining and sterilizing bacteria mostly due to low local blood concentration of lesion, have great toxic and side effect, and easily lead to diseases such as liver disease, deafness and the like if taken for a long time. If performing an operation, the course of treatment is long, cost is high, and patients are damaged both physically and mentally. In order to solve the above problems, the invention brings forward a diet therapy for treating cervical tuberculous lymphadenitis. The diet therapy is characterized in that the combination formula comprises 48-52 g of polished rice, 4-8 g of deer-horn glue, 1-5 g of cinnamon, 1-5 g of ephedra stem, 1-5 g of liquorice, 1-5 g of semen brassicae, 1-5 g of roasted ginger and 18-22 g of prepared rehmannia root. The diet therapy of the invention has no toxic or side effect, has good efficacy, needs no operation, is low-cost and maintains physical and mental health of people.
NEW MATERIAL:The 6-iodoacyclouridine derivative of formula I (R&lt;1&gt; is H, halogen or lower alkyl). EXAMPLE:5-Methyl-6-iodoacyclouridine. USE:A drug. An active component of an antitumor agent. It is administered at a rate of 0.1-1g of the active component daily for adult once a day or in divided doses. PREPARATION:The compound of formula I can be produced by reacting a compound of formula II (R&lt;2&gt; is protecting group) with a lithiation agent (e.g. lithium diisopropylamide), reacting the resultant compound of formula IV with an iodinating agent (e.g. I2) to obtain a compound of formula III and eliminating the protecting group from the obtained compound.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain an external anti-pruritic agent excellent in anti-pruritic effect, effective for relaxation of skin pruritus such as atopic dermatitis, senile xerosis and pruritus in winder season, free from adverse effect even when continuously used and excellent also in safety, a cosmetic composition, a bathing agent composition and a cleansing agent composition each containing the anti-pruritic agent.  &lt;P&gt;SOLUTION: The external anti-pruritic agent is composed of an extract of a composition which is similar to prescription of traditional Chinese medicine called as Unseiin, namely an extract of a mixture of 3-4 pts. wt. Angeliace Radix with 3-4 pts. wt. Rehmanniae radix, 3-4 pts. wt. Paeoniae Radix, 3-4 pts. wt. Cnidium rhizome, 1-1.5 pts. wt. Coptidis Rhizoma, 1.5-3 pts. wt. Scutellariae radix, 1.5-2 pts. wt. fruit of Gardenia jasminoides and 1-1.5 Phellodendri Cortex, and exhibits synergistically excellent anti-pruritic effect. The cosmetic composition, the bathing agent composition and a cleansing agent composition comprise each the external anti-pruritic agent.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
Transthyretin (TTR), a tetrameric thyroxine (T4) carrier protein, is associated with a variety of amyloid diseases. Derivative of biphenyl ethers (BPE), which are shown to interact with a high affinity to its T4 binding site thereby preventing its aggregation and fibrillogenesis. They prevent fibrillogenesis by stabilizing the tetrameric ground state of transthyretin. Two compounds (2-(5-mercapto-[1,3,4]oxadiazol-2-yl)-phenol and 2,3,6-trichloro-N-(4H-[1,2,4]triazol-3-yl) exhibit the ability to arrest TTR amyloidosis. The dissociation constants for the binding of BPEs and compound 11 and 12 to TTR correlate with their efficacies of inhibiting amyloidosis. They also have the ability to inhibit the elongation of intermediate fibrils as well as show nearly complete (&gt;90%) disruption of the preformed fibrils. Biphenyl ethers and compounds 11 and 12 as very potent inhibitors of TTR fibrillization and inducible cytotoxicity.
A nose and throat anti-influenza solution is described that decreases the likelihood influenza infection and its spread. The solution&#39;s components are readily available and have been used to treat humans for other ailments previously, leading to an easily implemented, scalable, safe, and cost-effective solution. The core components of the solution include: specially denatured alcohol (SDA); Triton x-100; sodium saccharin; 1,8 cineole (eucalyptol); thymol; methyl salicylate; menthol; sorbitol and/or glycerin; sodium benzoate; poloxamer 407; polysorbate 80; and distilled water. Optionally, the solution also includes one or more of the following: citric acid;  sambucus nigra  agglutinin; a lectin that binds 2,3 sialic acid; nonoxynol-9; sialyllactose; a protease; a protease inhibitor; and/or chloroquine. The solution is applied to the nasal cavity via a pre-moistened cotton swab or a pre-moistened facial tissue and the solution is applied to the back of the throat via a spray, gum, or gargle solution. Further a nebulizer, atomizer, or inhaler can be used to apply the solution to the back of the throat, to the pharynx, and/or to the respiratory tract.
PURPOSE:To obtain a new compound excellent in safety to the skin, capable of rapidly making the dark skin into the pale-colored skin, thus useful for cosmetics or medicines. CONSTITUTION:A compound of formula I or II (R is 2-20C aliphatic hydrocarbon), e.g. 4&#39;-O-ethylglabridin or 2&#39;-O-ethylglabridin. This compound of formula I or II can be obtained by the following process: glabridin of formula III is made to react with a halide of the formula R-X (X is Cl, Br or I) in a solvent (e.g. DMF) in the presence of a base (e.g. potassium carbonate) at room temperature to 200 deg.C, and the product is extracted with ethyl acetate, concentrated under reduced pressures and then purified. The compound of formula I or II as active ingredient is formulated at 0.001-10wt.% in a cosmetic or medicine.
PURPOSE: To obtain a naphthoylguanidine derivative represented by a specific formula, capable of manifesting excellent inhibiting actions on an Na&lt;+&gt; /H&lt;+&gt; exchange mechanism and useful as a medicine for disorder induced by acidosis in ischemia of the myocardium, e.g. myocardial necrosis or arrhythmia. CONSTITUTION: This derivative of formula I (R is H, a halogen or an alkoxy), e.g. 2-naphthoylguanidine. Furthermore, the objective compound is preferably obtained by reacting a compound of formula II (L is a halogen, methoxy, phenoxy, methylthio, phenylthio, ethoxycarbonyloxy or N-succinimidoyloxy) with guanidine in an amount of 1 to 12 equiv. based on the compound of formula II in an inert organic solvent such as methanol under conditions of cooling with ice or boiling temperature of the solvent for 1-24hr.
&lt;P&gt;PROBLEM TO BE SOLVED: To improve convenience in the case of changing the patient attribute information of inspection data related with a sample.  &lt;P&gt;SOLUTION: An attribute information updating terminal 60 transmits a patient attribute information acquisition request to an information processor (electronic medical record server 30, medical image server 50) for managing patient attribute information, and obtains patient attribute information corresponding to the acquisition request. The attribute information update terminal 60 generates an instruction (update target HL7 reference sample inspection result data and overwrite instruction) to update the patient attribute information of inspection data stored and managed by an inspection data management server 70 based on the patient attribute information. The attribute information update terminal 60 transmits the update target HL7 reference sample inspection result data and the overwrite instruction to the inspection data management server 70. The inspection data management server 70 updates the original HL7 reference sample inspection result data based on the update target HL7 reference sample inspection result data and the overwrite instruction.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a system for applying a vast amount of medical image data to CAD algorithms in an environment where new image modalities are being added.  &lt;P&gt;SOLUTION: A dispatcher dynamically accepts cases from external devices and manages distribution of the cases among a plurality of image processing servers 3. The dispatcher comprises a job dispatcher process for creating a child dispatcher process for each connection to an external device in one-to-one correspondence, and a registration service 13 for managing operating status information for the plurality of image processing servers. Each child process is assigned responsibility for managing an association for a connection. Each child dispatcher process is allocated its own dedicated cache memory for temporary storage of incoming image files. Thus, a large number of cases can be managed with a high throughput limited only by an amount of main memory in a computer running the dispatcher.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
PURPOSE:To provide a fat emulsion suitable for intravenous administration of a 2,3-dihydro-1H-indene derivative useful as a treating agent for hypoxia. CONSTITUTION:A fat emulsion containing (A) a 2,3-dihydro-1H-indene derivative represented by the formula (R&lt;1&gt;-R&lt;4&gt; are lower alkyl; R&lt;5&gt; is lower alkoxy; A is lower alkylene), (B) a pharmaceutically permissible oil component and (C) water as the essential components in a ratio of about 0.1-50W/V%, preferably about 5-25W/V% (B) based on the whole fat emulsion and &lt;=2 pts.wt., preferably about 0.01-1 pts.wt. (A) based on 100 pts.wt. (B). The above-mentioned fat emulsion is an excellent drug even in the intravenous administration capable of administering when the drug component (A) is required to rapidly show its effect and can also be orally administrated. In addition, in comparison with the conventional drugs, transport into the brain is very rapid and this fat emulsion is resistive to inactivation in vivo and liable to be distributed especially to lesions by the intake into phagocytes. This fatty emulsion, therefore, enables efficient accumulation of the drug component to lesions so that its remarkably excellent drug effect may be shown.
The present invention discloses the molecular mechanism of anti-aging properties of antcin M (ANM). This invention has found that human normal dermal fibroblast (HNDF) accelerates the arrest and aging in G0/G1 phase after exposure to high-glucose (HG, 30 mM) for 3 days. Experiments confirmed that co-treatment with ANM (10[mu]M) may significantly reduce HG-induced growth arrest and promoted cell proliferation. Further analysis revealed that ANM can inhibit HG-induced G1-S transitional protein reduction, such as cyclin D, cyclin E, CDK4, CDK6, CDK2 and protein retinoblastoma (pRb). In addition, under the ANM treatment, transcriptional activation of Nrf2 can induce the antioxidant genes HO-1 and NQO-1 and eliminates the HG-induced reactive oxygen species (ROS). It was demonstrated that ANM treatment can eliminate stress-induced premature senescence (SIPS) in the presence of HG by reducing the activity of senescence-associated [beta]-galactosidase (SA-[beta]-gal). This activity can be demonstrated by reducing the acetylated P21CIP1, p16INK4A and p53/FoxO1 of marker proteins associated with aging. In addition, cells administrated with ANM may enhance HG-induced expression of the aging-associated marker protein SMP30 and increased the expression of SIRT-1 as well as prevented the reduction of SIRT-1. This protection was confirmed by the consistency of inhibiting the phosphorylation of SIRT-1 at Ser47 by blocking the upstream kinases of p38 MAPK and JNK/SAPK. Further analysis showed that ANM protects some SIRT-1 silenced cells from HG-induced aging, and similar effect can be observed in Nrf2 silenced cells. However, a complete loss of this protective effect was observed in cells both Nrf2 and SIRT-1 are knockdown and eliminated, indicating that the antioxidant defense of Nrf2 and the deacetylation activity of the deacetylated SIRT-1 mediators contribute to the anti-aging activity of ANM in vitro. The results of the in vivo studies show that the survival rate of ANM-treated Caenorhabditis elegans increases during the HG-induced oxidative stress injury period. In addition, ANM significantly prolongs the elegans&#39;s life. Based on the above results, this invention clearly shows that ANM has potential application value for preventing or combating aging and related diseases caused by aging.
&lt;P&gt;PROBLEM TO BE SOLVED: To allow a user to safely disclose a personal information database to persons other than himself or to organizations.  &lt;P&gt;SOLUTION: A personal terminal 50 transmits to a relay server 40 a request to disclose the user&#39;s electronic chart information to a hospital D. The relay server 40 sets an authority to disclose the user&#39;s chart information to the first hospital D. The personal terminal 50 sends a notice to the first hospital&#39;s terminal 60 indicating that the authority has been set in the relay server 40. The first hospital&#39;s terminal 60 transmits to the relay server 40 the request to disclose the user&#39;s chart information. The relay server 40 transmits to a second hospital data server 10 the request to disclose the chart information. If the request to disclose the electronic chart information that has been transmitted from the relay server 40 is legitimate, the second hospital data server 10 transmits the electronic chart information to the relay server 40. Upon receiving the electronic chart information, the relay server 40 transmits the electronic chart information to the first hospital&#39;s terminal 60.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
The invention discloses a traditional Chinese medicine formula for treating chronic colitis. The traditional Chinese medicine formula for treating the chronic colitis comprises, by weight, 8-10 parts of baical skullcap roots, 10-12 parts of Chinese magnoliavine fruit, 10-12 parts of medicinal evodia fruit, 15-20 parts of lotus seeds, 25-30 parts of gordon enryale seeds, 15-20 parts of humifuse euphorbia herb, 20-25 parts of red halloysite, 20-25 parts of purple lythrum herb, 3-4 parts of medicine terminalia fruit, 20-25 parts of chicken&#39;s gizzard-membrane, 15-20 parts of hawthorn fruit, 20-25 parts of carbonized sanguisorba roots, 10-12 parts of coptis roots, 3-4 parts of amur corktree bark, 5-8 parts of nutmeg, 10-12 parts of kudzuvine roots, 2-5 parts of roasted largehead atractylodes rhizomes, 2-4 parts of white lablab bean hull, 4-5 parts of leaves of bruguiera sexangula (Lour.) Poir. and 2-4 parts of roots of aconitum finetianum Hand.Mazz.. The traditional Chinese medicine formula for treating the chronic colitis is simple, feasible in preparation method, notable in curative effect and capable of invigorating the spleen to remove dampness, invigorating the spleen-stomach, replenishing qi, warming the kidney, astringing the intestines and promoting the circulation of qi to remove stagnation. The traditional Chinese medicine formula has unique curative effect and is high in curative ratio and difficult to recur when being used for treating the chronic colitis.
FIELD: medicine, obstetrics, prophylaxis. SUBSTANCE: it is suggested to prescribe a food additive named &#34;Bumivit-C&#34; at the dosage of 15-20 g daily since the 21st-23d wk of gestation period. The method enables to increase efficiency in preventing pyelonephritis by 95.65%, decrease the frequency of complications occurring in the course of pregnancy. It is characterized by the absence of negative impact upon a fetus along with strengthening the maternal organism. EFFECT: higher efficiency of prophylaxis. 3 ex, 1 tbl
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a calcium L-threonate preparation whose elution with gastric juice can be prevented to enhance bioutility.  &lt;P&gt;SOLUTION: This oral administration composition containing the calcium L-threonate is characterized by containing a hydroxycarboxylic acid except L-threonic acid and L-ascorbic acid. The hydroxycarboxylic acid is preferably citric acid, lactic acid or malic acid. It is preferable that the content of the hydroxycarboxylic acid is 0.1 to 10 mass % based on the calcium L-threonate. The dosage form is preferably a tablet. It is preferable that the tablet is coated with an enteric coating. The enteric coating is preferably selected from gelatin, shellac, zein, ethyl cellulose, and methacrylic acid copolymers.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
The embodiment of the utility model discloses vaccine recognition device relates to image recognition technical field. The vaccine recognition device comprises a base station, a first image acquisition unit, a second image acquisition unit and a recognition processing module. Wherein, first image acquisition unit can form the collection region on the base station, and the collection region is used for placing the bacterin. The second image acquisition unit is arranged on the base station and positioned on two sides of the acquisition area. The identification processing module is used for receiving the image information of the vaccine acquired by the first image acquisition unit and the second image acquisition unit and carrying out identification verification on the identification information of the image information. Because second image acquisition unit is located the both sides of gathering the region, consequently, compare with first image acquisition unit and can follow the angle of difference and carry out image acquisition to the bacterin for bacterin recognition device can obtain the multiaspect image, improves identification information&#39;s integrality, and then improves the accuracy of discernment result.